Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
167,500
-71,500 (-29.92%)
Jul 21, 2026, 2:40 PM KST
Sam Chun Dang Pharm. Revenue
Sam Chun Dang Pharm. had revenue of 64.87B KRW in the quarter ending March 31, 2026, with 28.15% growth. This brings the company's revenue in the last twelve months to 246.05B, up 15.47% year-over-year. In the year 2025, Sam Chun Dang Pharm. had annual revenue of 231.81B with 9.90% growth.
Revenue (ttm)
246.05B
Revenue Growth
+15.47%
P/S Ratio
22.74
Revenue / Employee
570.89M
Employees
431
Market Cap
5.59T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 231.81B | 20.88B | 9.90% |
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% |
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% |
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% |
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Yuhan | 2.22T |
| Hanmi Pharm. | 1.55T |
| Samsung Epis Holdings | 1.51T |
| PharmaResearch | 565.48B |
| ALTEOGEN | 203.76B |
| LigaChem Biosciences | 125.87B |